Products & Innovation / CNSide

CNSide®

CNSide®, pronounced “see-inside,” is a cerebrospinal fluid assay platform for primary and metastatic CNS cancers. From one cerebrospinal fluid (CSF) sample, it detects and quantifies tumor cells and profiles the molecular targets that can help guide treatment.

One assay platform, multiple jobs.

CNSide® is a CLIA laboratory-developed test that does two things from the same spinal-fluid sample:

For a clinician, that changes what a CSF test can do: more sensitive detection than CSF cytology, a way to see whether treatment is working, and molecular targets that can change the therapy a patient receives.

Detection and monitoring

It captures and counts tumor cells in the CSF, giving a quantitative measure of disease that can be followed over time, not the yes-or-no answer of standard CSF cytology.

Biomarker characterization

Through a next-generation sequencing collaboration with Genomic Testing Cooperative, it profiles DNA and RNA across the tumor’s molecular targets, to help match patients to therapy.

From a CSF sample, CNSide® offers two tests that can be ordered individually or together:

CNSide® combines tumor cell enumeration with biomarker and genomic analysis to provide actionable information from a minimally invasive sample that can be collected longitudinally to monitor disease over time.

Test 1: Tumor cell detection and biomarker characterization

CNSide® captures and identifies tumor cells in the CSF, providing a quantitative tumor cell count rather than a binary positive or negative result.

Immunocytochemistry (ICC) and fluorescence in situ hybridization (FISH) characterize clinically relevant protein expression and genomic alterations in tumor cells identified in the CSF. Available Q4 2026.

Test 2: Genomic profiling

Next-generation sequencing (NGS) analyzes tumor-derived DNA and RNA across a broad panel of clinically relevant genes to identify molecular alterations that may help inform treatment decisions.

Man in glasses and a white shirt speaking during an interview in a bright, modern lounge.

Why CNSide® exists.

Our VP of Research & Development on the gap CNSide® fills, how the assay works, and what a quantitative result changes for a clinician.

What the data shows in practice.

CNSide® fits across the care pathway: at diagnosis, in treatment decisions, and in response monitoring. Its primary focus is leptomeningeal metastases, with further applications in primary and other metastatic CNS cancers.

Adoption is measurable, too: a recent multicenter analysis covered 613 CNSide® assays ordered by 19 physicians across 5 institutions.1 Since 2020, more than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions, supporting clinical decision-making across academic and community oncology practices nationwide.2

2.8x

2.8x the diagnostic sensitivity of standard CSF cytology.

90%

Influenced clinical management in more than 90% of leptomeningeal metastases cases.

60%

Identified HER2-positive tumor cells in the CSF of 60% of breast cancer patients whose primary tumors were HER2-negative.

Now part of the diagnostic standard.

The updated NCCN CNS Cancers Guidelines now include CSF circulating tumor cell analysis alongside tumor-derived DNA, expanding the leptomeningeal metastases (LM) diagnostic standard beyond cytology, so ordering CSF analysis like that of CNSide® now sits within guideline-supported practice.

1. FORESEE study (NCT05414123), presented at SNO 2024 and the 2025 SNO/ASCO CNS Metastases Conference.

2. These tests were performed by Biocept, Inc., CNSide’s original developer, prior to Cerenome’s (then Plus Therapeutics) acquisition of the CNSide platform on April 26, 2024.

Smiling woman with dark hair in a navy jacket in a softly lit room.

“CNSide® is a more sensitive and definitive test for LM and has the potential to permit earlier diagnosis, manage our patients with more diagnostic precision, and hopefully improve therapeutic outcomes.”

Priya U. Kumthekar, MD
Neuro-Oncologist, Northwestern University

Availability & Access

Commercially available and reimbursed.

Evidence only matters if a clinician can act on it, which means being able to order the test and have a viable path to reimbursement. CNSide® provides both.

Map of 43 institutions that offer CNSide®. They are also listed after the map.

  • Allina Health

    913 E 26th Street, Suite 304
    Minneapolis, MN 55404

    (612) 863-3200

    Dr. Williams

  • Asthra Health

    2811 Wilshire Blvd #790
    Santa Monica, CA 90403

    (310) 870-7260

    Dr. Santosh Kesari

  • Atrium / Advocate Health

    9201 University City Blvd
    Charlotte, NC 28223

    (704) 687-8622

    Dr. Carol J. Farhangfar

  • Baylor Scott & White

    300 University Blvd, Building A
    Round Rock, TX 78665

    (512) 509-0100

    Dr. Levacic
    Dr. Murillo

  • Capital Health

    1 Capital Way
    Pennington, NJ 08534

    (800) 637-2374

    Dr. David Redjal

  • Clearview Cancer

    3601 CCI Drive NW
    Huntsville, AL 35805

    (256) 705-4224

    Dr. John F. Gleason Jr

  • Cleveland Clinic Ohio

    10201 Carnegie Ave
    Cleveland, OH 44106

    (216) 636-0007

    Dr. Dhawan
    Dr. Lucas
    Dr. Torres-Trejo

  • Columbia University

    710 W 168th Street
    New York, NY 10032

    (212) 305-2862

    Dr. Diaz Ordonez
    Dr. Haggiagi
    Dr. Pan

  • CommonSpirit

    605 Glenwood Drive, Suite 200
    Chattanooga, TN 37404

    (423) 495-7730

    Dr. Rana

  • Georgetown

    3800 Reservoir Rd NW
    Washington, DC 20007

    (202) 444-2000

    Dr. Claudine Janet Diana Isaacs

  • Holy Cross Health

    4725 N Federal Highway
    Fort Lauderdale, FL 33308

    (954) 771-8000

    Dr. Azzi
    Dr. Segota

  • HonorHealth

    3621 N Wells Fargo Ave
    Scottsdale, AZ 85251

    (623) 238-7600

    Dr. Azadi

  • Houston Methodist

    6565 Fannin St
    Houston, TX 77030

    (713) 790-3311

    Dr. Michael Youssef

  • Huntsman Cancer Institute

    1950 Circle of Hope
    Salt Lake City, UT 84112

    (801) 585-0250

    Dr. Malani

  • Inova Cancer Center

    8081 Innovation Park Dr
    Fairfax, VA 22031

    (571) 472-4724

    Dr. Meaghan Roy-O'Reilly
    Dr. Catherine Wood
    Dr. Adam Cohen

  • Kootenai Health

    700 W Ironwood Drive, Suite 130
    Coeur d’Alene, ID 83814

    (208) 625-4700

    Dr. Allen

  • Louisiana State University Health

    433 Bolivar St
    New Orleans, LA 70112-7021

    (504) 568-4808

    Dr. Yazmin Odia

  • LSU / LCMC Health

    1111 Medical Center Blvd, Suite S-750
    Marrero, LA 70072

    (504) 340-6976

    Dr. Odia

  • Mayo Clinic Arizona

    5777 E Mayo Blvd
    Phoenix, AZ 85054

    (480) 342-2000

    Dr. Shannon Ensign

  • Mayo Clinic Florida

    4500 San Pablo Road
    Jacksonville, FL 32224

    (904) 953-2000

    Dr. Cordova

  • Mayo Clinic Minnesota

    200 First Street SW
    Rochester, MN 55905

    (507) 284-2511

    Dr. Sener

  • New York University Langone Health

    530 1st Ave, 10W
    New York, NY 10061

    (646) 929-7800

    Dr. Jonathan Yang
    Dr. Alexandra Gewirtz

  • Northwestern Medicine – Chicago

    675 N St Clair St, Suite 20-100
    Chicago, IL 60611-5975

  • Northwestern Medicine – Warrenville

    4405 Weaver Pkwy
    Warrenville, IL 60555

    (630) 352-5450

    Dr. Robin Buerki

  • Providence St. Joe

    501 S Buena Vista St
    Burbank, CA 91505

    (818) 843-5111

    Dr. Tran

  • Providence St. Jude

    2151 N Harbor Blvd, Suite 3100
    Fullerton, CA 92835

    (714) 446-5830

    Dr. Jose Carrillo

  • Rutgers

    210 Somerset Street, 14th Floor
    New Brunswick, NJ 08901

    (732) 235-2465

    Dr. Shaikh
    Dr. Vojnic

  • Stanford Medicine

    875 Blake Wilbur Dr, Clinic D, MC 6510
    Stanford, CA 94305

    (650) 723-4000

    Dr. Seema Nagpal
    Dr. Lawrence Recht
    Dr. Toni Cao
    Dr. David Rogawski
    Dr. Kate Therkelsen

  • Sutter Health

    1580 Valencia St, Floor 6
    San Francisco, CA 94110

    (415) 641-6566

    Dr. Sharma Akansksha

  • Texas Oncology – Houston Medical Center

    1350 First Colony Blvd
    Sugar Land, TX 77479

    (713) 795-0202

    Dr. Maria Morales

  • Texas Oncology – Sugar Land

    1350 First Colony Blvd
    Sugar Land, TX 77479

    (281) 277-5200

    Dr. Lee

  • The Queen’s Medical Center

    1301 Punchbowl Street
    Honolulu, HI 96813

    (808) 691-8777

    Dr. Hara

  • Trinity Health

    44405 Woodward Ave, H35
    Pontiac, MI 48341-2985

    (248) 858-3190

    Dr. Imlay

  • UC San Diego Health

    3855 Health Sciences Drive
    La Jolla, CA 92093

    (858) 657-8737

    Dr. David Piccioni

  • UH Seidman Cancer Center

    11100 Euclid Ave
    Cleveland, OH 44106

    (216) 844-1000

    Dr. Li Yi

  • University of Alabama at Birmingham

    2000 6th Ave S, Floor 2
    Birmingham, AL 35233

    (205) 801-8986

    Dr. Brown
    Dr. Sizemore

  • University of Michigan

    1500 E Medical Center Drive, Floor 1
    Ann Arbor, MI 48109-5902

    (734) 647-8902

    Dr. Fortunato

  • University of Rochester

    90 Crittenden Blvd
    Rochester, NY 14642

    (585) 275-5830

    Dr. Hemminger

  • UPMC

    5150 Centre Ave
    Pittsburgh, PA 15232

    (412) 648-9891

    Dr. Jan Drappatz

  • UT Health San Antonio

    7979 Wurzbach Rd, 4th Floor
    San Antonio, TX 78229

    (210) 567-7000

    Dr. Andrew Brenner

  • UW / Fred Hutchinson

    1959 NE Pacific Street, Floor 7
    Seattle, WA 98195

    (206) 598-2282

    Dr. Lanman
    Dr. Venur

  • VCU Health

    417 N 11th Street
    Richmond, VA 23219

    (804) 828-9350

    Dr. Stocksdale

  • Yale Medicine

    5520 Park Ave
    Trumbull, CT 06611

    (203) 502-8400

    Dr. Nicholas Blondin

A real accredited test.

CNSide® is a laboratory-developed test (LDT), developed by CNSide Diagnostics, LLC, and performed in a CLIA-licensed, CAP-accredited laboratory.

Its own billing code.

A dedicated AMA Proprietary Laboratory Analyses (PLA) code, 0640U, for the CNSide® tumor cell enumeration test, effective July 1, 2026.

Reimbursed and adopted.

CNSide® Diagnostics holds a Provider Transaction Access Number (PTAN), has established commercial payer coverage, and is already in clinical use at a growing number of centers.

How CNSide® advances treatment.

Within Cerenome’s platform, CNSide® does more than diagnose. It’s the assay used in the ReSPECT-LM clinical trial to measure tumor cells in the CSF, tracking how leptomeningeal metastases respond to the REYOBIQ™ investigational treatment. The same readout that guides a clinician’s decisions helps advance the therapeutics behind them.

Order CNSide®, view specimen requirements, and read full test details at cnside-dx.com.